Jardiance (empagliflozin): A Breakthrough in Cardiovascular Outcomes

Jardiance (empagliflozin): A Breakthrough in Cardiovascular Outcomes
Event on 2017-06-29 18:30:00
Jardiance (empagliflozin): A Breakthrough in Cardiovascular Outcomes Indication and Limitations of Use: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. Jardiance is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Reception starts at 6:15pm, program starts at 6:30pm Speaker: Mark Nathan MD Cardiologist   Please Register By:  6/22/17  (THURSDAY) CSHP members are free of charge, and non-members are charged  for future events planning  If you sign up and are no longer able to attend, please contact Leon Kung at kung.leon@gmail.com at least 48 hours prior to the event. ++ THERE IS NO CE FOR THIS EVENT ++ FAQ: Where can I contact the organizer with any questions? Contact CSHP North Coast President-elect Leon Kung at kung.leon@gmail.com Do I have to bring my printed ticket to the event? No, your name will be on the list. I am not currently a CSHP North Coast Chapter member, can I still attend? Yes! Preference will be given to CSHP member but non-members are also very welcome to this event! Non-members will be charged a fee to go towards future educational events.   Hope to see you there!

at Stark's Steakhouse
521 Adams Street
Santa Rosa, United States

avatar

Comment

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :confused: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen: